文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

RNA 在癌症免疫疗法中的作用：解锁免疫系统的潜力。

RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System.

机构信息

Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.

出版信息

Clin Cancer Res. 2022 Sep 15;28(18):3929-3939. doi: 10.1158/1078-0432.CCR-21-3304.

DOI:10.1158/1078-0432.CCR-21-3304
PMID:35583609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9475240/
Abstract

Recent advances in the manufacturing, modification, purification, and cellular delivery of ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a broad array of applications. The approval of two SARS-CoV-2-targeting mRNA-based vaccines has highlighted the advances of this technology. Offering rapid and straightforward manufacturing, clinical safety, and versatility, this paves the way for RNA therapeutics to expand into cancer immunotherapy. Together with ongoing trials on RNA cancer vaccination and cellular therapy, RNA therapeutics could be introduced into clinical practice, possibly stewarding future personalized approaches. In the present review, we discuss recent advances in RNA-based immuno-oncology together with an update on ongoing clinical applications and their current challenges.

摘要

近年来，在制造、修饰、纯化和细胞递送上的进展，使得 RNA 为基础的治疗方法在广泛的应用领域得以发展。两种针对 SARS-CoV-2 的靶向 mRNA 疫苗的批准凸显了这一技术的进步。该技术具有快速、直接的制造、临床安全性和多功能性，为 RNA 治疗方法扩展到癌症免疫治疗铺平了道路。随着 RNA 癌症疫苗接种和细胞治疗的持续试验，RNA 治疗方法可能会被引入临床实践，为未来的个性化方法提供可能。在本综述中，我们讨论了 RNA 免疫肿瘤学的最新进展，并更新了正在进行的临床应用及其当前的挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a14/9475240/c3224c768b2c/3929fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a14/9475240/916d8ac7e1f7/3929fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a14/9475240/7a21508660bf/3929fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a14/9475240/c3224c768b2c/3929fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a14/9475240/916d8ac7e1f7/3929fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a14/9475240/7a21508660bf/3929fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a14/9475240/c3224c768b2c/3929fig3.jpg

相似文献

[1]
RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System.

Clin Cancer Res. 2022-9-15

[2]
mRNA-based therapeutic strategies for cancer treatment.

Mol Ther. 2024-9-4

[3]
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.

Arch Razi Inst. 2021-3

[4]
Advances in mRNA-based drug discovery in cancer immunotherapy.

Expert Opin Drug Discov. 2022-1

[5]
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery.

Adv Drug Deliv Rev. 2023-8

[6]
mRNA vaccines for cancer immunotherapy.

Front Immunol. 2022

[7]
Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing.

Biomolecules. 2023-10-9

[8]
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise.

J Clin Invest. 2022-3-15

[9]
Personalized Immuno-Oncology.

Med Princ Pract. 2021

[10]
COVID-19 mRNA vaccines: Platforms and current developments.

Mol Ther. 2022-5-4

引用本文的文献

[1]
Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities.

Vaccines (Basel). 2025-6-26

[2]
mRNA vaccines and SiRNAs targeting cancer immunotherapy: challenges and opportunities.

Discov Oncol. 2025-7-5

[3]
Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?

Med Oncol. 2025-6-19

[4]
Chemically modified non-coding RNAs in cancer.

Expert Rev Mol Med. 2025-6-9

[5]
Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy.

Front Immunol. 2024-11-25

[6]
Colorectal Cancer Immunotherapy: State of the Art and Future Directions.

Gastro Hep Adv. 2023

[7]
Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines.

Vaccines (Basel). 2023-10-25

[8]
Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists.

Mol Ther Nucleic Acids. 2023-7-28

[9]
Involvement of lncRNAs in the tumor microenvironment: a new property of tumor immunity.

Cancer Biol Med. 2023-8-26

本文引用的文献

[1]
Identification of neoantigens for individualized therapeutic cancer vaccines.

Nat Rev Drug Discov. 2022-4

[2]
CAR T cells produced in vivo to treat cardiac injury.

Science. 2022-1-7

[3]
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs.

Drug Metab Pharmacokinet. 2021-12

[4]
Recent Advances in Experimental Dendritic Cell Vaccines for Cancer.

Front Oncol. 2021-9-23

[5]
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.

Eur J Cancer. 2021-11

[6]
Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment.

Front Oncol. 2021-8-31

[7]
The tangled history of mRNA vaccines.

Nature. 2021-9

[8]
Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models.

Sci Transl Med. 2021-9-8

[9]
Therapeutic cancer vaccines revamping: technology advancements and pitfalls.

Ann Oncol. 2021-12

[10]
The infinite possibilities of RNA therapeutics.

J Ind Microbiol Biotechnol. 2021-12-23

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索